PAMA

November 25th, 2016 - M. Ann Bachman, BSMT (ASCP), CLC (AMT), CMPM
Categories:   Medicare Physician Fee Schedule (MPFSDB)   Laboratory|Pathology  
0 Votes - Sign in to vote or comment.

The Clinical Laboratory Fee Schedule (CLFS) final rule, "Medicare Program: Medicare Clinical Diagnostic Laboratory Tests Payment System" (CMS-16F) implements PAMA, the Protecting Access to Medicare Act of 2014. The purpose of this rule is to more closely align CLFS payments under Medicare with payments made by private payers. CMS perceives that Medicare pays significantly more for some tests than do some private payers.

Under this rule, "applicable" laboratories are required to report revenue information to CMS. "Applicable" laboratories are those laboratories that:

  • Bill Medicare for laboratory testing under their own billing NPI number;

  • Received more than $12,500 from the CLFS for traditional tests (Advanced Diagnostic Laboratory Tests will be handled separately; see explanation below) during the period of January 1, 2016 - June 30, 2016; and

  • Received more than 50% of their Medicare revenues from laboratory and physician services during that same data-gathering period.

Applicable laboratories, or reporting entities, must first report to CMS during the reporting period of January 1 – March 31, 2017 the following "applicable" information:

  • How much each private payer reimbursed for each laboratory test performed and

  • How many of each test were billed to each payer

CMS will use this information to calculate new (reduced) reimbursement amounts they will pay for tests performed for Medicare beneficiaries. Failure to report, or omission or misrepresentation, may result in fines of up to $10,000 per day. PAMA does not allow voluntary reporting by laboratories that do not meet the definition of an applicable laboratory. Reporting will be required every three years. The maximum reimbursement reduction for any given clinical laboratory test will be:

  • 10% in 2018

  • 10% in 2019

  • 10% in 2020

  • 15% in 2021

  • 15% in 2022

  • 15% in 2023

An Advanced Diagnostic Laboratory Test, or ALDT, is defined by PAMA as "a clinical diagnostic laboratory test covered under this part that is offered and furnished only by a single laboratory (or a corporate entity that owns multiple laboratories) and not sold for use by a laboratory other than the original developing laboratory (or a successor owner) and meets one of the following criteria:

(A) The test is an analysis of multiple biomarkers of DNA, RNA, or proteins combined with a unique algorithm to yield a single patient-specific result and yields clinical diagnostic information that cannot be obtained from any other tests or combination of tests, and may include other assays.

(B) The test is cleared or approved by the Food and Drug Administration (FDA).

(C) The test meets other similar criteria established by the Secretary."

The minimum threshold of $12,500 does not apply to ALDTs. However, for laboratories performing ALDTs and traditional testing, this applies only to the ALDTs. Reimbursement for new ALDTs will be the actual list charge during the new ALDT initial period, which is three full calendar quarters. The local Medicare Administrative Contractor (MAC) will determine the payment amount for a new ALDT prior to the new ALDT initial period, from the time the test is first offered prior to the beginning of the next full calendar quarter.

Applicable information for ALDTs must be gathered annually from January 1 - June 20 and reported to CMS the following January 1 - March 31. The American Medical Association, which creates and owns CPT codes, will create a new coding process specifically to meet the requirements of PAMA. Either the AMA will create CPT codes or CMS will create HCPCS Level II codes to identify new and existing ALDTs as well as CLDTs that are cleared or approved by the FDA. The Office of the Inspector General (OIG) has determined that Medicare could save as much as $910 million annually. Medicare currently spends approximately $7 billion annually for clinical diagnostic laboratory testing.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

Medicare Updates -- SNF, Neurostimulators, Ambulance Fee Schedule and more (2022-10-20)
October 27th, 2022 - CMS - MLNConnects
Skilled Nursing Facility Provider Preview Reports: Review by November 14 - Help Your Patients Make Informed Health Care Decisions - Ambulance Fee Schedule: CY 2023 Ambulance Inflation Factor & Productivity Adjustment - Compliance - Implanted Spinal Neurostimulators: Document Medical Records - Claims, Pricers, & Codes...
2023 Evaluation & Management Updates Free Webinar
October 24th, 2022 - Aimee Wilcox
Congratulations on a successful 2021 implementation of the Evaluation and Management (E/M) changes! That was a big change, but now an even bigger change is headed your way for inpatient and all other E/M categories. How great is it that almost all of the E/M categories will now be scored based on medical decision making (MDM) or total provider time? Standardized scoring and one set of E/M guidelines has the potential of bringing about a change or improvement of provider fatigue due to over regulation and documentation burden.
Are Leading Queries Prohibited by Law or Lore?
October 13th, 2022 - Erica E. Remer
AHIMA released its CDI Practice Brief Monday. At Yom Kippur services, I found myself thinking about the question Dr. Ronald Hirsch posed to me the day before. My rabbi was talking in her sermon about the difference between halacha and minhag. Halacha is law; it is the prescriptions...
2023 ICD-10-CM Guideline Changes
October 13th, 2022 - Chris Woolstenhulme
View the ICD-10-CM Guideline Changes for 2023 Chapter 19 (Injury, poisoning, and certain other consequences of external causes [S00-T88])The guidelines clarify that coders do not need to see a change in the patient’s condition to assign an underdosing code. According to the updated guidelines, “Documentation that the patient is taking less ...
Z Codes: Understanding Palliative Care and Related Z Codes
October 11th, 2022 - Gloryanne Bryant
Palliative care is often considered to be hospice and comfort care. Palliative care is sometimes used interchangeably with “comfort care” and then again sometimes with “hospice care.”  But these terms do have slightly different meanings and sometimes the meaning varies depending on who is stating it. The National...
2023 ICD-10-CM Code Changes
October 6th, 2022 - Christine Woolstenhulme, CPC, CMRS, QCC, QMCS
In 2022 there were 159 new codes; the 2023 ICD-10-CM code update includes 1,176 new, 28 revised, and 287 deleted codes, a substantial change from last year. The 2023 ICD-10-CM codes are to be used for discharges from October 1, 2022 through September 30, 2023, and for patient encounters from ...
Yes, You Have What It Takes To Lead Your Practice And Your Profession
September 20th, 2022 - Kem Tolliver
If you’ve been in any healthcare role for more than two years, you’ve seen quite a bit of change. And guess what, it’s not over. We are living and working in uncertain times. This climate requires each of us to step outside of our comfort zones to lead exactly where we stand. It’s not required of one to have a “title” to lead. What is required, however, is a willingness to trust your instincts, look for answers and rely on your team.



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2022 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association